Festina lente: Hydroxychloroquine, COVID-19 and the role of the rheumatologist

Elizabeth R. Graef, Jean W. Liew, Michael S. Putman, Julia F. Simard, Emily Sirotich, Francis Berenbaum, Alí Duarte-García, Rebecca Grainger, Carly Harrison, Maximilian F. Konig, Peter Korsten, Laurie Proulx, Dawn P. Richards, Philip C. Robinson, Sebastian E. Sattui, Manuel Francisco Ugarte-Gil, Kristen J. Young, Alfred H.J. Kim, Jeffrey A. Sparks

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations
Original languageEnglish
Pages (from-to)S734-S736
JournalAnnals of the Rheumatic Diseases
Issue number6
StatePublished - 1 Jun 2020

Bibliographical note

Funding Information:
Competing interests FB reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, Novartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica and 4P Pharma. RG reports personal fees from Pfizer, Cornerstones, Jannsen and Novartis. PK reports personal fees from GlaxoSmithKline, Sanofi-Aventis, Pfizer, Abbvie, Novartis Pharma, Eli Lilly and Bristol-Myers Squibb. AHJK reports grants from NIH (National Institutes of Health)/NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) and Rheumatology Research Foundation and personal fees from Exagen Diagnostics and GlaxoSmithKline. JAS reports grants from NIH/NIAID (National Institute of Allergy and Infectious Diseases)/Autoimmune Centers of Excellence, the Rheumatology Research Foundation, the Brigham Research Institute and the R. Bruce and Joan M. Mickey Research Scholar Fund as well as personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen and Optum.


  • antirheumatic agents
  • health services research
  • hydroxychloroquine

Cite this